Active, not recruitingNCT07198191

SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

Studying MODY

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Yonsei University
Principal Investigator
Yongcheol Kim, MD, PhD
Yonsei University Health System, Yongin Severance Hospital
Intervention
SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin)(drug)
Enrollment
200000 target
Eligibility
19 years · All sexes
Timeline
20142026

Study locations (1)

Collaborators

Chong Kun Dang Pharmaceutical Corp. · Health Insurance Review & Assessment Service

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07198191 on ClinicalTrials.gov

Other trials for MODY

Additional recruiting or active studies for the same condition.

See all trials for MODY

← Back to all trials